A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
Status:
Recruiting
Trial end date:
2022-07-13
Target enrollment:
Participant gender:
Summary
The trial is a placebo-controlled, double-blinded within cohorts, randomized, multiple
ascending dose trial with a sequential trial design. The primary outcome is to investigate
the safety and tolerability of ascending subcutaneous weekly doses of NNC0361-0041 plasmid in
patients with T1D.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)